Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
December 21 2020 - 8:02AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of: December 2020
Commission file number: 001-36578
ENLIVEX THERAPEUTICS LTD.
(Translation of registrant’s name
into English)
14 Einstein Street, Nes Ziona, Israel
7403618
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ☐
On December 21, 2020, Enlivex Therapeutics
Ltd., a company organized under the laws of the State of Israel, issued a press release announcing the pre-print publication of
a manuscript on medRxiv.org, which presents positive safety and efficacy data from a completed Phase Ib investigator-initiated
clinical trial evaluating AllocetraTM in patients with severe sepsis. A copy of such press release is furnished as Exhibit
99.1 to this Report on Form 6-K and incorporated herein by reference.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
Enlivex Therapeutics Ltd.
|
|
|
(Registrant)
|
|
|
|
|
|
By:
|
/s/ Oren Hershkovitz
|
|
|
Name:
Title:
|
Oren Hershkovitz
Chief Executive Officer
|
Date: December 21, 2020
2
Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enlivex Therapeutics (NASDAQ:ENLV)
Historical Stock Chart
From Apr 2023 to Apr 2024
